Your browser doesn't support javascript.
loading
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai, Wanwisa; Huo, Jiandong; Zhou, Daming; Zahradník, Jirí; Supasa, Piyada; Liu, Chang; Duyvesteyn, Helen M E; Ginn, Helen M; Mentzer, Alexander J; Tuekprakhon, Aekkachai; Nutalai, Rungtiwa; Wang, Beibei; Dijokaite, Aiste; Khan, Suman; Avinoam, Ori; Bahar, Mohammad; Skelly, Donal; Adele, Sandra; Johnson, Sile Ann; Amini, Ali; Ritter, Thomas G; Mason, Chris; Dold, Christina; Pan, Daniel; Assadi, Sara; Bellass, Adam; Omo-Dare, Nicola; Koeckerling, David; Flaxman, Amy; Jenkin, Daniel; Aley, Parvinder K; Voysey, Merryn; Costa Clemens, Sue Ann; Naveca, Felipe Gomes; Nascimento, Valdinete; Nascimento, Fernanda; Fernandes da Costa, Cristiano; Resende, Paola Cristina; Pauvolid-Correa, Alex; Siqueira, Marilda M; Baillie, Vicky; Serafin, Natali; Kwatra, Gaurav; Da Silva, Kelly; Madhi, Shabir A; Nunes, Marta C; Malik, Tariq; Openshaw, Peter J M; Baillie, J Kenneth; Semple, Malcolm G.
Afiliação
  • Dejnirattisai W; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Huo J; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Zhou D; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Zahradník J; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Supasa P; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Liu C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.
  • Duyvesteyn HME; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Ginn HM; Diamond Light Source Ltd, Harwell Science & Innovation Campus, Didcot, UK.
  • Mentzer AJ; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Tuekprakhon A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Nutalai R; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Wang B; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Dijokaite A; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Khan S; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Avinoam O; Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Bahar M; Division of Structural Biology, Nuffield Department of Medicine, University of Oxford, The Wellcome Centre for Human Genetics, Oxford, UK.
  • Skelly D; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
  • Adele S; Peter Medawar Building for Pathogen Research, Oxford, UK.
  • Johnson SA; Peter Medawar Building for Pathogen Research, Oxford, UK.
  • Amini A; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Peter Medawar Building for Pathogen Research, Oxford, UK; Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
  • Ritter TG; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Mason C; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
  • Dold C; NIHR Oxford Biomedical Research Centre, Oxford, UK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Pan D; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK; Department of Respiratory Sciences, University of Leicester, Leicester, UK.
  • Assadi S; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Bellass A; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Omo-Dare N; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Koeckerling D; Medical Sciences Division, University of Oxford, Oxford, UK.
  • Flaxman A; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Jenkin D; Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Aley PK; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Voysey M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
  • Costa Clemens SA; Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.
  • Naveca FG; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Nascimento V; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Nascimento F; Laboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Manaus, Amazonas, Brazil.
  • Fernandes da Costa C; Fundação de Vigilância em Saúde do Amazonas, Manaus, Amazonas, Brazil.
  • Resende PC; Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Pauvolid-Correa A; Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil; Department of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX, USA.
  • Siqueira MM; Laboratorio de vírus respiratórios-IOC/FIOCRUZ, Rio de Janeiro, Brazil.
  • Baillie V; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology, National Research Foundation, South African Research C
  • Serafin N; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology, National Research Foundation, South African Research C
  • Kwatra G; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology, National Research Foundation, South African Research C
  • Da Silva K; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology, National Research Foundation, South African Research C
  • Madhi SA; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology, National Research Foundation, South African Research C
  • Nunes MC; South African Medical Research Council, Vaccines and Infectious Diseases Analytics Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; Department of Science and Technology, National Research Foundation, South African Research C
  • Malik T; National Infection Service, Public Health England (PHE), Porton Down, Salisbury, UK.
  • Openshaw PJM; National Heart & Lung Institute, Imperial College, London, UK.
  • Baillie JK; Genetics and Genomics, Roslin Institute, University of Edinburgh, Edinburgh, UK.
  • Semple MG; NIHR Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
Cell ; 185(3): 467-484.e15, 2022 02 03.
Article em En | MEDLINE | ID: mdl-35081335
On 24th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B.1.1.529 was announced, containing far more mutations in Spike (S) than previously reported variants. Neutralization titers of Omicron by sera from vaccinees and convalescent subjects infected with early pandemic Alpha, Beta, Gamma, or Delta are substantially reduced, or the sera failed to neutralize. Titers against Omicron are boosted by third vaccine doses and are high in both vaccinated individuals and those infected by Delta. Mutations in Omicron knock out or substantially reduce neutralization by most of the large panel of potent monoclonal antibodies and antibodies under commercial development. Omicron S has structural changes from earlier viruses and uses mutations that confer tight binding to ACE2 to unleash evolution driven by immune escape. This leads to a large number of mutations in the ACE2 binding site and rebalances receptor affinity to that of earlier pandemic viruses.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Cell Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Cell Ano de publicação: 2022 Tipo de documento: Article